NRX Pharmaceuticals, Inc. Contract Liability (Deferred Revenue)
NRX Pharmaceuticals, Inc. (NRXP) had Contract Liability (Deferred Revenue) of $56.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2022-11-14
- 2022-09-30: Contract with Customer, Liability, Current $56.00K.
- 2022-06-30: Contract with Customer, Liability, Current $19.00K.
- 2022-03-31: Contract with Customer, Liability, Current $135.00K.
- 2021-12-31: Contract with Customer, Liability, Current $292.00K.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2022-09-30 | $56.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $19.00K 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $135.00K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $292.00K 10-Q · filed 2022-11-14 | |
| 2021-09-30 | $1.26M 10-Q/A · filed 2022-08-12 | $775.26K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $22.85M 10-Q/A · filed 2022-08-12 | $515.02K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |